Ikeda Mako, Nakahara Wataru, Asako Mizuki, Umeki Yuka, Matsuoka Yoshiki, Terakawa Takuya, Matsunaga Hitomi, Iwasa Yuki, Saito Riko, Iwama Yuki, Matsui Takahiro, Oka Kazumasa, Ueda Shuji
Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan.
Department of Clinical Laboratory, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan.
Case Rep Hematol. 2023 Feb 25;2023:3628712. doi: 10.1155/2023/3628712. eCollection 2023.
Mixed phenotype acute leukemia (MPAL) is characterized by leukemic blasts that express markers of multiple lineages. Compared with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), MPAL is considered to have a poor treatment outcome. We report a case of MPAL T/myeloid not otherwise specified that was initially presented as multilineage lymphoblastic lymphoma and subsequently developed into leukemic MPAL. An acute lymphoblastic leukemia-based treatment regimen was ineffective, but azacitidine and venetoclax therapy resulted in hematological complete remission. Our case suggests that multilineage lymphoblastic lymphoma should be considered to be the same disease as MPAL, albeit with different clinical presentations. Optimal treatment for MPAL has not been established yet, but azacitidine and venetoclax therapy may be a potential approach.
混合表型急性白血病（MPAL）的特征是白血病原始细胞表达多种谱系的标志物。与急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）相比，MPAL被认为治疗效果较差。我们报告一例未另行指定的MPAL T/髓系病例，该病例最初表现为多谱系淋巴细胞淋巴瘤，随后发展为白血病性MPAL。基于急性淋巴细胞白血病的治疗方案无效，但阿扎胞苷和维奈克拉治疗导致血液学完全缓解。我们的病例表明，多谱系淋巴细胞淋巴瘤应被视为与MPAL相同的疾病，尽管临床表现不同。MPAL的最佳治疗方案尚未确立，但阿扎胞苷和维奈克拉治疗可能是一种潜在的方法。
